Last update Dec. 24, 2022
Synthetic drug and nucleoside analogue which is structurally related to guanine with antiviral activity. It is used in infants and newborns for treatment of respiratory syncytial virus (RSV) and adenovirus (Ronchi 2014). It is used along with interferon for treatment of hepatitis C, authorized on these cases from the 3 years of life. (Christensen 2014, Durmaz 2012). Oral administration in patients with chronic hepatitis C.
At latest update no published data on excretion into breast milk were found.
Its large volume of distribution makes it unlikely that may occur the passage of significant amounts to the milk, but its very long elimination half-life would favor it
Its low oral bioavailability hinder the passage toward infant’s plasma from ingested milk, except in preterm milk and immediate neonatal period, for which there may be an increased intestinal permeability.
Since it is used as treatment on infants and its pharmacokinetic data are favorable, it should be regarded as compatible with breastfeeding for short-term exposures, however, to be cautiously used on long-term treatments.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity. (Mahadevan 2006)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM